Skip to content
  • About
  • Board
  • News
  • Sign Up
  • Contact

Visit

vjhemonc logo
VJOncology
Logo
  • Home (current)
  • Diseases
    Genitourinary
    Lung
    Head and Neck
    Breast
    Gynecological
    Skin
    View all Diseases
    • Topics
      Treatment
      Early Diagnosis
      Nursing
      Pharmacy
      Supportive Care
      Policy
      View all Topics
      • Conferences
        NCRI
        2019
        ISOPP
        2019
        ESMO
        2019
        EONS
        2019
        ASCO
        2019
        ELCC
        2019
        View all Conferences
        • Features
        • Podcasts
          • About
          • Board
          • News
          • Sign Up
          • Contact

        Atezolizumab

        4:06
        Strategies to reduce drug costs
        Mark Ratain
        3:59
        Interventional pharmoeconomics to reduce the cost of therapy
        Mark Ratain
        3:45
        Molecular target therapy in pancreatic and liver cancer
        Hani Babiker
        4:20
        IMvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer
        Thomas Powles
        1:50
        IMpower133: atezolizumab, carboplatin plus etoposide for SCLC
        Martin Reck
        3:19
        PD1 & PDL1 inhibitors for mUC, where are we?
        Petros Grivas
        2:57
        Phase 3 IMvigor130 results: atezolizumab in untreated metastatic urothelial carcinoma
        Enrique Grande
        7:21
        IMvigor130: atezolizumab +/- platinum-based chemo upfront for advanced urothelial carcinoma
        Enrique Grande
        4:18
        IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC
        David Spigel
        3:58
        Atezolizumab and bevacizumab for upfront unresectable HCC
        Michael Lee
        1:02
        Non-clear cell sarcamatoid kidney cancer treatment updates
        Rana McKay
        4:02
        Atezolizumab plus bevacizumab in non-clear cell, sarcomatoid kidney cancer
        Rana McKay
        1:00
        IMpassion130: Implications
        Peter Schmid
        2:30
        IMpassion130: immunotherapy for TNBC
        Peter Schmid
        1:47
        TNBC: work to be done
        Peter Schmid
        0:47
        Atezolizumab for TNBC
        Erika Hamilton
        • 1
        • 2
        • 3
        • 4
        • 5
        • 6
        • Next
        vjoncology logo VJOncology is intended for Healthcare Professionals only

        By choosing to continue, you are confirming that you are a healthcare professional

        VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

        Please enter your details if you would like to receive the latest oncology news and updates

        Continue
        Disease channels
        • Genitourinary
        • Lung
        • Head and Neck
        • Breast
        • Gynecological
        • Skin
        • View all
        Join our community

        Keep up-to-date via social media

        Sign up for email updates

        Get great new content delivered to your inbox

        Sign up
        mmp logo

        Magdalen Centre
        The Oxford Science Park
        Oxford OX4 4GA, United Kingdom

        VJOncology logo
        The content of VJOncology is intended for healthcare professionals
        • Cookie Policy
        • Privacy Policy
        • Terms of Use
        • Editorial Policy